New 'Double-Target' cell therapy tested in kids with Tough-to-Treat leukemia
NCT ID NCT06777979
Summary
This early-stage study is testing the safety of a new type of CAR T-cell therapy for children and young adults (up to age 21) whose acute lymphoblastic leukemia has come back or hasn't responded to other treatments. The therapy uses the patient's own modified immune cells designed to attack two targets (CD19 and CD22) on the leukemia cells. The main goal is to find a safe dose and understand the side effects before testing how well it works against the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
St. Jude Children's Research Hospital
RECRUITINGMemphis, Tennessee, 38105, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.